Skyline Medical Awarded Innovative Technology Contract from Vizient, Inc. for STREAMWAY ® System

MINNEAPOLIS, March 01, 2017 -- Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or “the Company”),producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal has received an Innovative Technology contract from Vizient, Inc. With an annual purchasing volume of almost $100 billion, Vizient is the largest, member-driven health care performance improvement company in the country. The contract was based on a recommendation of STREAMWAY by hospital experts with expertise in this category who serve on one of Vizient’s member-led councils. Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization’s care delivery and business model.

Published: 01 March 2017

Written by Editor

Corindus Vascular Robotics Announces Private Placement for $45 Million

Financing Supports Launch Momentum of Next-Generation CorPath GRX System

Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a leading developer of precision vascular robotics, announced today that it has entered into a Securities Purchase Agreement pursuant to which it will issue and sell an aggregate of 67,941,346 shares of its common stock in a private placement at a purchase price of $0.6616 per share, resulting in aggregate gross proceeds to the Company of approximately $45,000,000. The closing of the transaction, which is subject to customary closing conditions, is expected to occur on or before March 15, 2017.

Published: 28 February 2017

Written by Editor

AMEX Up on News Financing

Microbot Medical Inc. Announces Significant Technology Patent Allowance in the U.S.

HINGHAM, Mass., Feb. 22, 2017 -- Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key technology patent. The Patent App. No. 14/348,610, covers a device for the prevention of shunt stenosis.

Two of the inventors include the Company’s co-founders, Harel Gadot and Professor Moshe Shoham. Mr. Gadot is the CEO, President and Chairman of Microbot Medical. Prof. Shoham, the Head of the Robotics lab at the Technion – Israel Institute of Technology, is on the Company’s Board of Directors and the Scientific Advisory Board. The patent rights are covered as a joint patent under an exclusive license agreement the Company has with the Technion.

Published: 22 February 2017

Written by Editor

Nasdaq Up on News Project Update

Medigus Receives Approval for Commencement of the First Multi-Center MUSE Clinical Study from CFDA in China

OMER, ISRAEL--(Feb 16, 2017) - Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced that the China Food and Drug Administration, or CFDA, has approved the commencement of the first multi-center MUSE™ Clinical Study in China.

Approval to start the multi-center MUSE™ clinical study was received after the CFDA reviewed the ethics committees' approval and agreements were in place with each center. Under Principal Investigator, Yunsheng Yang, Director of Gastroenterology Department Clinical center at 301 Hospital and chairman of Chinese Society of Gastroenterology, The General Hospital of People's Liberation Army in Beijing, the clinical study of approximately 62 patients, will take place at 5 centers across China:

Published: 16 February 2017

Written by Editor

Nasdaq Up on News Project Update

Hologic to Acquire Cynosure, Leader in Medical Aesthetics Systems and Technologies, in All-Cash Tender Offer that Combines Two Complementary Businesses

-Expands Hologic's Scientific and Commercial Expertise into Large, Adjacent Medical Device Segment Growing at Double-Digit Rate -

-Accelerates Hologic's Top- and Bottom-Line Growth Rates and is Immediately Accretive to Non-GAAP Earnings per Share -

MARLBOROUGH, Mass. and WESTFORD, Mass., Feb. 14, 2017 -- Hologic, Inc. (Nasdaq: HOLX), a leader in women's health, and Cynosure, Inc. (Nasdaq: CYNO), a leader in medical aesthetics systems and technologies, announced today they have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billion and an enterprise value of $1.44 billion net of cash.

Published: 14 February 2017

Written by Editor

Nasdaq M & A Up on News

Skyline Medical ( SKLN )

Skyline Medical Awarded Innovative Technology Contract from Vizient, Inc. for STREAMWAY ® System

Corindus Vascular Robotics ( CVRS )

Corindus Vascular Robotics Announces Private Placement for $45 Million

Microbot Medical Inc ( MBOT )

Microbot Medical Inc. Announces Significant Technology Patent Allowance in the U.S.

Medigus Ltd ( MDGS )

Medigus Receives Approval for Commencement of the First Multi-Center MUSE Clinical Study from CFDA in China

Cynosure Inc ( CYNO )

Hologic to Acquire Cynosure, Leader in Medical Aesthetics Systems and Technologies, in All-Cash Tender Offer that Combines Two Complementary Businesses